Suppr超能文献

引入一种整合的初级保健粪便免疫化学检测转诊途径,用于疑似结直肠癌症状的患者。

Introduction of an integrated primary care faecal immunochemical test referral pathway for patients with suspected colorectal cancer symptoms.

机构信息

Croydon University Hospital, London, UK.

Imperial College London, London, UK.

出版信息

Colorectal Dis. 2022 Dec;24(12):1526-1534. doi: 10.1111/codi.16294. Epub 2022 Aug 23.

Abstract

AIM

To determine the efficacy of a new 2-week wait pathway that uses the faecal immunochemical test (FIT) in primary care to triage patients with high and low risk symptoms suspicious of colorectal cancer (CRC). This service improvement pilot follows 2017 National Institute for Health and Care Excellence guidance, that recommended using FIT to guide referral of patients with low risk, but not high risk symptoms, which continue to be referrred on the 2-week pathway.

METHOD

Patients with high- and low-risk CRC symptoms were tested with FIT and those with faecal haemoglobin (f-Hb) ≥9.5 μg haemoglobin/g faeces (hereafter μg/g) were referred to secondary care. Results were tracked and primary care prompted to refer if timely referral was not made.

RESULTS

Between December 2019 and October 2020, 5672 patients presented to primary care with high and/or low risk symptoms warranting investigations. Of these, 622 (11%) patients were referred without a FIT, of whom 36 (5.8%) had CRC. The remaining 5050 patients had a FIT, of which 4187 (83%) were processed to produce a quantitative result. Of these, 1085 patients (25.9%) had an f-Hb ≥9.5 μg/g and of those, 982 patients (90.5%) were referred and 56 (5.7%) had CRC. A total of 3102 patients (74.1%) had an f-Hb <9.5 μg/g, of which 456 (14.7%) were referred and three (0.7%) had CRC. A total of 97 cancers were diagnosed with a cancer prevalence of 1.7%.

CONCLUSION

A 2-week wait pathway incorporating FIT as a triage tool can be implemented successfully in primary care to identify symptomatic patients at highest risk of CRC.

摘要

目的

确定一种新的 2 周等待途径在初级保健中的疗效,该途径使用粪便免疫化学测试(FIT)对疑似结直肠癌(CRC)的高风险和低风险症状患者进行分诊。这项服务改进试点遵循 2017 年国家卫生与保健卓越研究所的指导建议,该建议建议使用 FIT 来指导低风险但无高风险症状患者的转诊,这些患者继续在 2 周途径中转诊。

方法

对具有高风险和低风险 CRC 症状的患者进行 FIT 检测,粪便血红蛋白(f-Hb)≥9.5μg 血红蛋白/g 粪便(以下简称μg/g)的患者被转诊至二级保健。结果进行了跟踪,如果没有及时转诊,初级保健会收到提示。

结果

2019 年 12 月至 2020 年 10 月期间,5672 名具有高风险和/或低风险症状的患者到初级保健就诊,需要进行检查。其中,622 名(11%)患者未经 FIT 检测就被转诊,其中 36 名(5.8%)患有 CRC。其余 5050 名患者进行了 FIT 检测,其中 4187 名(83%)产生了定量结果。其中,1085 名患者(25.9%)的 f-Hb≥9.5μg/g,其中 982 名患者(90.5%)被转诊,56 名(5.7%)患有 CRC。共有 3102 名患者(74.1%)的 f-Hb<9.5μg/g,其中 456 名(14.7%)被转诊,3 名(0.7%)患有 CRC。共有 97 例癌症被诊断,癌症患病率为 1.7%。

结论

在初级保健中实施包含 FIT 作为分诊工具的 2 周等待途径,可以成功识别最有可能患有 CRC 的有症状患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验